European Pharmaceutical Review

FEBRUARY 1, 2023

billion in 2027 at a compound annual growth rate (CAGR) of 12.5 The post Pharmaceutical sterility testing market to grow from $2.07b in 2027 appeared first on European Pharmaceutical Review. A recent market report showed that the global pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2022 to $1.29

Pharmaceutical 98

Pharmaceutical Marketing Manufacturing Pharma 98

Fierce Pharma

SEPTEMBER 4, 2024

In his nine months as CEO, BioMarin’s new chief Alexander Hardy has so far overseen shakeups in the company’s leadership team, a slimdown of its R&D program and decisive action on the future of | The company's game plan includes five new indications for dwarfism drug Voxzogo through 2031, which could represent a $5 billion opportunity covering (..)

Patients 130

Patients 130

Pharmaceutical Technology

AUGUST 31, 2023

Alkermes settled the lawsuit with Teva, allowing the latter to market the generic version of Vivitrol from January 2027.

Marketing 52

Marketing 52

MedCity News

FEBRUARY 22, 2024

Perelel’s $10 million pledge comes in the form of product donations and funding grants and will go to the Magee-Womens Research Institute and the Good+Foundation through 2027.

108

108

World of DTC Marketing

JUNE 15, 2021

Billion by 2027, growing at a CAGR of 16.4% from 2020 to 2027. According to Verified Market Research, the Global Telehealth Market was valued at USD 21.17 Billion in 2019 and is projected to reach USD 71.44

Side effects 193

Side effects Insurance Doctors Pharma 193

World of DTC Marketing

MARCH 28, 2022

If the trend continues at the current rate, millennial treatment costs are still projected to be close to $4,500 annually, roughly 33 percent higher than Generation X’s at a comparable age, by 2027. That’s about $375 per month. And what are we doing about it?

Insurance 249

Insurance Ethics Healthcare Healthcare 249

Pharmaceutical Commerce

AUGUST 19, 2024

The 86,000 square-foot Køge facility will be fully functional by 2027.

81

81

PharmaTech

SEPTEMBER 12, 2024

Seventeen biologics and nine tides—five peptides and four oligonucleotides—were approved in 2023 alone, with further growth predicted.

52

52

Pharmaceutical Commerce

APRIL 5, 2023

Rise in value attributed to the ongoing decentralization of pharmacies.

Marketing 52

Marketing Pharma 52

Pharmacy Times

JANUARY 10, 2023

The report highlights the growth of personalized medicines with improved efficacy for rare, previously untreatable diseases.

Medicine 52

Medicine 52

European Pharmaceutical Review

AUGUST 27, 2024

Manufacturing of the biologic products in the expanded Sweden Biomanufacturing Center is planned to begin from Q4 of 2027, according to AstraZeneca. “We are happy about this investment in Södertälje, which demonstrates AstraZeneca’s commitment to innovation and manufacturing of biological medicines in Sweden”, Alfredsson continued.

Medicine 115

Medicine Manufacturing Pharmaceutical Patients 115

European Pharmaceutical Review

NOVEMBER 2, 2022

Somewhat ambitious: Meet three percent of GDP by 2027, building on aspirations set out by the Confederation of British Industry (CBI), the European Commission (EC) and opposition political parties. The government would need to invest an extra £1 billion in R&D by 2027. Private investment would also need to rise by £0.8

Government 98

Government Leads Manufacturing Medicine 98

PharmaTech

OCTOBER 26, 2023

As CMOs continue to invest in cell culture capacity, some are expected to surpass top in-house companies.

52

52

Pharmaceutical Technology

OCTOBER 6, 2023

Biologics are poised to overtake innovative small molecules in terms of sales revenue by 2027, with forecast sales of $120bn.

Sales 59

Sales 59

European Pharmaceutical Review

FEBRUARY 27, 2024

The facility has been designed to meet the highest environmental sustainability standards, to help Amgen’s reach its target of carbon neutrality in all operations by 2027, the company noted. .” Amgen Ohio is nearly 300,000 ft 2 in size and will employ 400 full-time staff.

Manufacturing 105

Manufacturing Food and Drug Administration Food Networking 105

Pharmaceutical Commerce

AUGUST 30, 2024

The 3PL plans to convert all its trucks to electric by 2027.

52

52

European Pharmaceutical Review

JUNE 26, 2024

Completion is expected between 2027 and 2029. This is compared to the company’s $3.9 (DKK DKK 26 billion) investment in 2023, not including acquisitions. Initial construction work has begun on the new facility. Haemophilia drug could reduce treated bleeding episodes … The post New US fill finish facility receives $4.1

Manufacturing 104

Manufacturing Pharmaceutical 104

Pharmaceutical Technology

MAY 23, 2024

The cost saving programme is expected run over multiple years and will save the company about $1.5bn by 2027.

52

52

Pharmaceutical Commerce

JANUARY 25, 2023

Annual report finds continuing impact of COVID-19 on global markets

Marketing 52

Marketing Medicine 52

European Pharmaceutical Review

OCTOBER 18, 2022

Global pharma contract manufacturing market to value $120bn by 2027… The post HPAPI contract manufacturing to value $14.6 billion by 2030 appeared first on European Pharmaceutical Review.

Manufacturing 105

Manufacturing Pharma Pharmaceutical Marketing 105

PharmaTech

OCTOBER 4, 2024

When the expansion is completed, Piramal expects manufacturing capacity to be increased by the first quarter of 2027 from 104 product batches per year to more than 240.

Manufacturing 52

Manufacturing 52

PharmaVoice

JULY 1, 2024

government, the latest spending projections reveal soon-to-be-implemented price caps will have an impact by 2027. As the first 10 drugs undergo price negotiations with the U.S.

Government 52

Government 52

European Pharmaceutical Review

OCTOBER 16, 2023

The new filling line is projected to be operational in 2027. Approximately 115 new jobs are expected to be created. Enhancing manufacturing capabilities The bioconjugates market is currently valued at $33 billion according to research by Lonza.

Manufacturing 105

Manufacturing Marketing Networking Pharmaceutical 105

European Pharmaceutical Review

DECEMBER 2, 2022

The facility is planned for completion in 2027. The investment will support the addition of new technologies to ensure Pfizer is ready to facilitate the next generation of medical innovations, and to help increase capacity for licensed and pipeline products in oncology, rare disease, inflammation & immunology and internal medicines.

Manufacturing 105

Manufacturing Medicine Networking Medical 105

pharmaphorum

JULY 15, 2022

The company – which announced plans to go public earlier this year – is addressing a growth market valued at around $25 billion in 2020 and estimated to grow at around 15% a year to reach $65 billion in 2027, according to market research company GMI. The post Akili digital therapeutic shows promise in lupus patients appeared first on.

Patients 129

Patients Engineering Marketing Medical 129

European Pharmaceutical Review

MAY 1, 2024

The new R&D building in Germany is expected to completed in 2027. “I am particularly looking forward to seeing how we will further develop the future of laboratory automation and digital research in Ludwigshafen in our pursuit of discovering and developing breakthrough medicines for patients.”

Pharmaceutical manufacturing 98

Pharmaceutical manufacturing Medicine Pharmaceutical Patients 98

European Pharmaceutical Review

MARCH 14, 2024

A global Phase III clinical trial is being planned, with an expected regulatory submission in 2027. The data from the studies suggested that the vaccine has “blockbuster potential”, according to SK bioscience.

Manufacturing 98

Manufacturing Marketing Medicine Pharma 98

Pharmaceutical Technology

MAY 19, 2023

AbbVie anticipates Rinvoq sales to exceed $7.5bn in 2025 and for the peak revenues from both drugs to exceed Humira’s peak sales by 2027.

Food and Drug Administration 105

Food and Drug Administration FDA Sales Food 105

pharmaphorum

JANUARY 10, 2023

The trial involves a single dose of AT845 delivered by intravenous infusion to a cohort of 12 patients with LOPD, and was due to complete last month with follow-up until early 2027. There has been no update from Astellas since the clinical hold was imposed last June.

Patients 119

Patients FDA 119

European Pharmaceutical Review

NOVEMBER 20, 2023

While the new site is anticipated to be operational at the start of 2027, the investment in Alzey is contingent upon finalisation of government permitting and local approvals, Eli Lilly stated. To support reliable medicine supply, since 2020, Eli Lilly has announced investments of over $11 billion in its global manufacturing footprint.

Manufacturing 98

Manufacturing Medicine Biopharma Engineering 98

European Pharmaceutical Review

JULY 18, 2022

Nebido is also patented until March 2024 in the European Union and until May 2027 in the United States. The long-acting injectable treatment for testosterone deficiency has been commercially approved in more than 80 countries.

Medicine 98

Medicine Physicians Competition Patients 98

PharmExec

FEBRUARY 9, 2024

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Marketing 40

Marketing 40

European Pharmaceutical Review

SEPTEMBER 21, 2023

The Novo Nordisk Foundation Cellerator is expected to be in operation in 2027. “We believe the Novo Nordisk Foundation Cellerator can be a leading player in Europe and a model for similar facilities around the world,” Professor Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation commented.

Manufacturing 116

Manufacturing Leads Networking Pharmaceutical 116

European Pharmaceutical Review

JUNE 15, 2023

Rapid microbiology testing market growth expected 2022 to 2027 The post Why is microbiological testing in medical device manufacturing important? Therefore, with “careful consideration and planning, manufacturers can develop reliable and accurate microbiology testing methods that ensure the safety and efficacy of their medical devices.”

Manufacturing 103

Manufacturing Medical Safety Transportation 103

European Pharmaceutical Review

FEBRUARY 8, 2023

Breyanzi sales will also be supplemented by the anticipated approval in chronic lymphocytic leukemia (CLL) in 2027, making it the first and only currently marketed CD19 CAR-T agent to penetrate the CLL market. Breyanzi will exhibit the largest compound annual growth rate (CAGR) at 30 percent, compared to Yescarta’s CAGR of 9 percent.

Marketing 98

Marketing Sales Physicians Patients 98

Pharmaceutical Technology

MARCH 15, 2023

The committee has also launched new targets for December 2027. Additionally, 50 of the private companies in the UK need to have a minimum of one ethnic minority director on the main board by December 2027. Under these targets, each FTSE 350 company will be required to set a percentage target for senior management positions.

Management 52

Management Pharma 52

European Pharmaceutical Review

MAY 4, 2023

According to Research and Markets 8 , the market for bispecific antibodies for cancer is forecasted to grow by $400 million during 2022-2027, due to the increasing prevalence of cancer worldwide. Global Bispecific Antibodies for Cancer Market 2023-2027. Personalized medicine at FDA. Internet] Personalized Medicine Coalition.

Food and Drug Administration 98

Food and Drug Administration Safety Patients Medicine 98